Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device

Nanjing Novlead Bio Files Hong Kong IPO – Nitric Oxide Therapy Specialist Targets Critical Care Market

Fineline Cube Mar 3, 2026
Company Deals

Boehringer Ingelheim Licenses Sitryx Autoimmune Program – $500M+ Deal for Oral Disease‑Modifying Therapy

Fineline Cube Mar 3, 2026
Company Deals

ArkBio Partners with Qilu Pharma on Azstarys China Commercialization – ADHD Therapy Market Entry

Fineline Cube Mar 3, 2026
Company Deals

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Fineline Cube Mar 2, 2026
Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II

Fineline Cube Mar 3, 2026
Company Drug

Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes

Fineline Cube Mar 3, 2026
Company Deals

BMS Expands CAR-T Collaboration with Cellares on Automation Tech

Fineline Cube Oct 12, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a technology transfer agreement with US-based Cellares,...

Company Drug

Henlius Pharmaceutical Secures GMP Compliance for PD-1 Inhibitor Serplulimab in Indonesia

Fineline Cube Oct 12, 2023

Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced that its partner, PT Kalbe Genexine...

Company Deals

Medilink Therapeutics Enters Global Licensing Agreement with BioNTech for HER3-Targeted Antibody Drug Conjugates

Fineline Cube Oct 12, 2023

Suzhou-based Medilink Therapeutics has announced a strategic cooperation and global licensing agreement with Germany-headquartered BioNTech...

Company Medical Device

Jiangsu BioPerfectus Secures NMPA Approval for Norovirus Nucleic Acid Detection Kit

Fineline Cube Oct 12, 2023

China-based Jiangsu BioPerfectus Technologies Co., Ltd (SHA: 688399), a leading manufacturer of in vitro diagnostic...

Company

Kintor Pharmaceutical Secures NMPA Approval for Phase II Study of GT1708F in Idiopathic Pulmonary Fibrosis

Fineline Cube Oct 12, 2023

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced that it has received approval from the...

Company Drug

Yiling Pharmaceutical Secures NMPA Approval for Phase I Study of G201-Na in Premenopausal Women

Fineline Cube Oct 12, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received approval from...

Company

Gritgen Therapeutics Commences Operations of Commercial GMP Facilities in Suzhou

Fineline Cube Oct 12, 2023

Suzhou-based gene therapy specialist, Gritgen Therapeutics Co., Ltd, has announced the validation completion and initiation...

Company Drug

GenFleet Therapeutics’ CDK9 Inhibitor SLS009 Earns Orphan Drug Status for AML

Fineline Cube Oct 12, 2023

Shanghai-based biotechnology company GenFleet Therapeutics has announced that its CDK9 inhibitor, SLS009 (GFH009), has received...

Company Medical Device

Cochlear’s Artificial Cochlear Sound Processor Gains NMPA Approval for Marketing in China

Fineline Cube Oct 11, 2023

Australia-based Cochlear has received marketing approval from the National Medical Products Administration (NMPA) for its...

Company Deals

Jiangsu Recbio Forms Strategic Cooperation for Vaccine Production in Zimbabwe

Fineline Cube Oct 11, 2023

China-based Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has announced a tripartite strategic cooperation agreement...

Company Drug

Roche’s Forimtamig Receives Tacit Approval for Multiple Myeloma Clinical Trials

Fineline Cube Oct 11, 2023

The Center for Drug Evaluation (CDE) has indicated that Swiss pharmaceutical giant Roche (SWX: ROG)...

Company Deals

Sanofi Partners with BioMap to Accelerate AI-Driven Drug Discovery

Fineline Cube Oct 11, 2023

France-based pharmaceutical giant Sanofi (EPA: SAN) has entered into a strategic partnership with US biotech...

Company Deals

Sino Biopharmaceutical Sells 84.2% Stake in Shanghai CP General Pharmaceutical

Fineline Cube Oct 11, 2023

China-based biotech company Sino Biopharmaceutical Ltd (HKG: 1177) has announced the sale of an 84.2%...

Company Deals

Jiangsu QYuns Therapeutics Plans IPO on Hong Kong Stock Exchange

Fineline Cube Oct 11, 2023

China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) has announced its intention to pursue an...

Company Drug

Janssen Unveils Promising Clinical Data on IL-23 Blockers for Psoriasis

Fineline Cube Oct 11, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) is showcasing new clinical data...

Company Medical Device

MicroPort Secures Market Approvals for ULYS ICDs and INVICTA Leads in Japan

Fineline Cube Oct 11, 2023

Shanghai-based MicroPort Scientific Corp. (HKG: 0853) has announced that its France-based subsidiary, MicroPort Cardiac Rhythm...

Policy / Regulatory

Hainan Implements New Regulations for Import Drugs and Medical Devices in Medical Tourism Zone

Fineline Cube Oct 11, 2023

The Hainan Medical Products Administration, in conjunction with Hainan’s Health Commission Bureau, has unveiled a...

Company

Bayer Opens First Cell Therapy Production Facility in the U.S. to Advance Research

Fineline Cube Oct 11, 2023

Bayer AG (ETR: BAYN) has inaugurated its first production site dedicated to cell therapies, marking...

Company Drug

AstraZeneca Seeks Approval for Capivasertib in Combination with Faslodex for Breast Cancer Treatment

Fineline Cube Oct 11, 2023

AstraZeneca (AZ, NASDAQ: AZN) has submitted a market approval filing for its Category 1 drug...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Anti-Tumor Drug Candidate SHR-2022

Fineline Cube Oct 10, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Posts pagination

1 … 425 426 427 … 629

Recent updates

  • MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation – Multi‑Branch Stent Graft Targets Complex Aortic Arch Lesions
  • Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II
  • Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes
  • Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension
  • Xellsmart’s iPSC Neural Therapy Cleared by NMPA and FDA – First “Off‑the‑Shelf” Cell Therapy for MSA‑P Enters Clinic
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Medical Device

MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation – Multi‑Branch Stent Graft Targets Complex Aortic Arch Lesions

Company Drug

Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II

Company Drug

Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes

Company Drug

Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.